Form 4: Nuvation Bio Director Robert Bazemore Granted Significant Stock Options

Nuvation Bio Inc. Director Robert Bazemore was granted 292,983 stock options with an exercise price of $2.03, aligning his interests with the company's long-term performance.

Summary

• Robert B. Bazemore, a Director of Nuvation Bio Inc. (NUVB), was granted 292,983 stock options.
• The options have an exercise price of $2.03 per share.
• The grant date for these options was May 21, 2025.
• The options are set to expire on May 20, 2035.
• 100% of the shares subject to the option will vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2025); or (ii) the next shareholder annual meeting.
• Vesting is contingent upon Mr. Bazemore's continuous service through the applicable vesting date.
• Following this transaction, Mr. Bazemore directly beneficially owns 292,983 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the stock option grant aligns the director's interests with the company's long-term performance, which is generally viewed favorably by investors. However, it does not represent a direct financial gain for the company or a significant operational update.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value of Nuvation Bio Inc.
• Equity compensation is a standard practice for attracting and retaining experienced board members.

Negatives

• The exercise of these options in the future could lead to a degree of share dilution, although this is a common aspect of equity compensation plans.

Risks

• The value of the stock options is subject to the future market price of Nuvation Bio Inc.'s Class A Common Stock, meaning the options may not be 'in the money' if the stock price does not exceed the exercise price.

Future Outlook

The vesting schedule indicates that the options are designed to incentivize the director's continued service to the company for at least one year or until the next shareholder annual meeting, aligning his future efforts with the company's success.

Industry Context

The granting of stock options to directors is a common and widely accepted practice across various industries, particularly in biotechnology and pharmaceuticals, to incentivize long-term commitment and align leadership interests with shareholder returns.

Corporate Governance

Related Party Transactions

• The grant of 292,983 stock options to Robert B. Bazemore, a Director of Nuvation Bio Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also improved alignment of director's interests with long-term shareholder value.
• Management/Board: Reinforces the compensation structure for directors, potentially aiding in retention and motivation.

Next Steps

• The stock options will vest on the earlier of May 21, 2025, or the next shareholder annual meeting, subject to the director's continuous service.
• Upon vesting, the director will have the right to exercise the options to purchase Class A Common Stock at the specified exercise price until the expiration date of May 20, 2035.

Key Dates

Recommendation

Keywords

Nuvation Bio, NUVB, Robert Bazemore, Stock Option, SEC Form 4, Director Compensation, Equity Grant, Vesting, Insider Transaction